Hosted on January 11, 2021. PeDRA President-Elect Anna Bruckner, MD, MSCS gave a presentation on basic biology underlying EB and recent advances in EB clinical research. Webinar sponsored by Amryt Research Ltd.
Understanding EB Biology and Recent Advances in EB Clinical Research and Q&A Session, Sponsored by Amryt Research Ltd.
Monday, January 11, 2021, 5:30 PM PST / 8:30 PM EST
Speaker: Anna Bruckner, MD, MSCS
Anna Bruckner, MD, MSCS
Dr. Bruckner is Associate Professor of Dermatology and Pediatrics and at the University of Colorado School of Medicine and Director of Pediatric Dermatology at Children’s Hospital Colorado. She attended Northwestern University as part of the Honors Program in Medical Education, earning her MD in 1997. She completed residencies pediatrics and dermatology at the University of Colorado followed by a fellowship in pediatric dermatology at the University of California San Francisco. She maintains board-certification in dermatology and pediatric dermatology.
Dr. Bruckner is passionate about improving outcomes and quality of life for children with skin disorders through patient care, research, education and advocacy. Her academic interests include genetic skin disorders – particularly epidermolysis bullosa (EB), vascular anomalies, atopic dermatitis, and complex patients. She is the principal investigator for the Epidermolysis Bullosa Clinical Research Consortium, a network of North American EB care centers collaborating in clinic research aimed at improving the care and outcomes for patients with EB.
Dr. Bruckner is a founding member of the Pediatric Dermatology Research Alliance (PeDRA) and served on PeDRA’s Executive Committee until 2016. She is now the 2022 President-Elect.
PeDRA will evaluate content for suitability for its audience but is not responsible for the creation of content, selection of speakers, or delivery of presentations. Please email us at email@example.com with any questions or concerns. This webinar is being hosted by PeDRA and sponsored by Amryt Research Ltd.
Date of preparation: December 2020. VV-MED-00552